NASDAQ : MBRX

Moleculin Biotech, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 8.72 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 8.49M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Details

NameMoleculin Biotech, Inc.
SectorHealthcare
IndustryBiotechnology
Employees17
Founded2015
Ipo Date2016-06-02
CeoWalter Klemp
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS60855D5077
Cusip60855D507
Cik0001659617
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Walter V. KlempChairman, President and Chief Executive Officer
Jonathan P. Foster CPAExecutive Vice President and Chief Financial Officer
Dr. Donald H. Picker Ph.D.Chief Scientific Officer
Dr. Waldemar Priebe Ph.D.Co-Founder, Founding Scientist and Chairman of Scientific Advisory Board
Dr. John Paul Waymack M.D., Sc.D.Senior Chief Medical Officer

Contact

Address5300 Memorial Drive, Suite 950, Houston, Texas 77007, United States
Phone713 300 5160
Websitehttps://moleculin.com